Your browser is no longer supported. Please, upgrade your browser.
Enochian Biosciences, Inc.
Index- P/E- EPS (ttm)-0.23 Insider Own0.10% Shs Outstand46.66M Perf Week7.40%
Market Cap176.71M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float14.64M Perf Month18.24%
Income-10.90M PEG- EPS next Q- Inst Own5.30% Short Float9.84% Perf Quarter-1.63%
Sales- P/S- EPS this Y48.60% Inst Trans0.23% Short Ratio5.06 Perf Half Y15.97%
Book/sh3.47 P/B1.05 EPS next Y- ROA-6.20% Target Price- Perf Year-1.89%
Cash/sh0.07 P/C51.97 EPS next 5Y- ROE-6.60% 52W Range2.60 - 13.43 Perf YTD23.05%
Dividend- P/FCF- EPS past 5Y2.60% ROI- 52W High-72.97% Beta0.29
Dividend %- Quick Ratio2.60 Sales past 5Y- Gross Margin- 52W Low39.62% ATR0.28
Employees10 Current Ratio2.60 Sales Q/Q- Oper. Margin- RSI (14)53.48 Volatility10.27% 7.60%
OptionableNo Debt/Eq0.04 EPS Q/Q-69.10% Profit Margin- Rel Volume0.73 Prev Close3.78
ShortableYes LT Debt/Eq0.04 Earnings- Payout- Avg Volume284.42K Price3.63
Recom- SMA207.57% SMA502.01% SMA2002.86% Volume208,123 Change-3.97%
Apr-30-21 03:42AM  
Mar-24-21 06:00PM  
Feb-22-21 05:15PM  
Nov-01-20 09:35AM  
Sep-10-20 12:50AM  
Jul-27-20 08:00AM  
Jun-08-20 07:30AM  
May-14-20 09:50AM  
May-13-20 08:00AM  
Apr-23-20 07:00AM  
Apr-09-20 10:00AM  
Feb-24-20 07:30AM  
Feb-03-20 07:30AM  
Jan-06-20 07:30AM  
Dec-10-19 07:00AM  
Nov-25-19 07:00AM  
Nov-21-19 10:30AM  
Oct-31-19 04:17PM  
Oct-26-19 10:18AM  
Jun-03-19 07:00AM  
Apr-29-19 09:19AM  
Mar-07-19 12:45PM  
Feb-01-19 02:31PM  
Jan-16-19 04:00PM  
Jan-07-19 08:30AM  
Jan-04-19 08:00AM  
Dec-05-18 08:30AM  
Dec-03-18 08:30AM  
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.